Effect of 2-year treatment with low-dose rosuvastatin on intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 17, 2011, Pages 2599-2604

  Riccioni, Graziano ^a   Cipollone, Francesco ^b   Santovito, Donato ^b   Scotti, Luca ^b   D'Orazio, Nicolantonio ^b   Mezzetti, Andrea ^b   Bucciarelli, Tonino ^b  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Atherosclerosis; Carotid arteries; Cholesterol; Intima media thickness; Rosuvastatin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LOW DRUG DOSE; MALE; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TRIGLYCERIDES;

EID: 81255195282     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.618497     Document Type: Article

References (22)

1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57
2. Hansson G, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-19
3. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness - a systematic review and meta-analysis. Circulation 2007;115:459-67
4. Crouse JR III, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. JAMA 2007;297:1344-53
5. Kasliwal R, Wilton LV, Cornelius V, et al. Safety profile of rosuvastatin: results of a prescription-event monitoring studyof 11,680 patients. Drug Saf 2007;30:157-70
6. Rubba P, Marotta G, Gentile M. Efficacy and safety of rosuvastatin in the management of dyslipidemia. Vasc Health Risk Manag 2009;5:343-52
7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-21
8. European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70 - 99%) or with mild (0 - 29%) carotid stenosis. Lancet 1991;337:1235-43
9. Kanters SD, Algra A, van Leeuwen MS, Banga JD. Reproducibility of in vivo carotid intima-media thicknessmeasurements. Stroke 1997;28:665-71
10. Touboul PJ, Hennerici MG, Adams H, et al. Mannheim carotid intima-media thickness consensus (2004 - 2006). Cerebrovasc Dis 2007;23:75-80
11. Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. Stroke 1993;24:1297-304
12. Crouse JR III, Byngton RP, Bond MG. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC II). Am J Cardiol 1995;75:455-9
13. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-65
14. Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-6
15. Sillesen H. Statins and their use in preventing carotid disease. Curr Atheroscler Rep 2009;11:309-14
16. Riccioni G. Statins and carotid intima-media thickness reduction: an up-to-date review. Curr Med Chem 2009;16:1799-805
17. Furberg CD, Adams HP, Applegate WB, et al. Effect of lovastatin on early atherosclerosis and cardiovascular events. Circulation 1994;90:1679-87
18. Amarenco P, Labreuche J, Lavallee Touboul PJ. Statins in stroke prevention and carotid atherosclerosis. Stroke 2004;35:2902-9
19. Smilde TJ, van Wissen S, Wollersheim H, et al. Effects of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP). Lancet 2001;357:577-81
20. Taylor AJ, Kent SM, Flaherty PJ, et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness (ARBITER). Circulation 2002;106:2055-60
21. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43
22. Underhill HR, Yuan C, Zhao XQ, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008;155:584.e1-8